@the_news_21
Indian government approved Bharat Biotech’s Covaxin for emergency use for those aged above two years. While Zydus Cadila’s ZyCoV-D had previously received approval for all individuals aged 12 and above, this is the first jab to cater to younger children.
According to a report on Monday quoting an AIIMS professor, the latest trials indicate that the safety and immunogenicity of Covaxin are almost the same in children, as adults above 18 years of age. The trials were done in three age brackets. The first group examined was between 12 -18 years, the second group was between 6- 12 years and the third age group was between 2-6 years.
“At first, we finished the examination of people aged between 12- 18 years and then subsequently other groups. Covaxin’s vaccine safety and immunogenicity are almost the same. However, the final results of these trials are awaited. We had already carried out trials on the adult population. For children, we are waiting for the results,” Dr. Rai who was the principal investigator of Covaxin trials on children had said on Monday.
